PDF(Pubmed)
Abstract：
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. In particular, patients who suffer from ischemic heart disease (IHD) that is not amenable to surgical or percutaneous revascularization techniques have limited treatment options. Furthermore, after revascularization is successfully implemented, there are a number of pathophysiological changes to the myocardium, including but not limited to ischemia-reperfusion injury, necrosis, altered inflammation, tissue remodeling, and dyskinetic wall motion. Electrospinning, a nanofiber scaffold fabrication technique, has recently emerged as an attractive option as a potential therapeutic platform for the treatment of cardiovascular disease. Electrospun scaffolds made of biocompatible materials have the ability to mimic the native extracellular matrix and are compatible with drug delivery. These inherent properties, combined with ease of customization and a low cost of production, have made electrospun scaffolds an active area of research for the treatment of cardiovascular disease. In this review, we aim to discuss the current state of electrospinning from the fundamentals of scaffold creation to the current role of electrospun materials as both bioengineered extracellular matrices and drug delivery vehicles in the treatment of CVD, with a special emphasis on the potential clinical applications in myocardial ischemia.
摘要：
心血管疾病（CVD）仍然是全球死亡的主要原因。特别是,患有缺血性心脏病(IHD)且不适合手术或经皮血运重建技术的患者的治疗选择有限.此外，血运重建成功实施后，心肌有许多病理生理变化，包括但不限于缺血再灌注损伤，坏死,炎症改变，组织重塑,和运动障碍的壁运动。静电纺丝,纳米纤维支架制造技术，作为治疗心血管疾病的潜在治疗平台，最近已成为一种有吸引力的选择。由生物相容性材料制成的静电纺丝支架具有模拟天然细胞外基质的能力并且与药物递送相容。这些固有的属性，结合易于定制和低成本的生产，使静电纺丝支架成为治疗心血管疾病的活跃研究领域。在这次审查中,我们的目的是讨论静电纺丝的当前状态，从支架产生的基本原理到静电纺丝材料作为生物工程细胞外基质和药物递送载体在CVD治疗中的当前作用，特别强调心肌缺血的潜在临床应用。
